Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1213037 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $0.81Day −0.98%Mkt cap $55M1Y −75.5%Off 52W high −78.7%Vol (1Y) 88.8%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,361 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest17.7% of sh out |
| Days to cover6.2d |
| 13F net flow (QoQ)−3.16% |
| Top-10 13F concentration78.0% |
| Next report (est.)2026-08-13 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$525,000 |
| Earnings (TTM)-$44.8M |
| ROE−71.5% |
| Net margin−7732.0% |
| Sales growth 3Y15.4% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−71.2% |
| 1Y−75.5% |
| 3Y−54.2% |
| 5Y−84.8% |
| Since incept. (ann.)−38.5% |
Total return through 2026-07-29 · series begins 2021-02-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)88.8% |
| Ann. volatility (3Y)105.5% |
| Sharpe (1Y)−1.25 |
| Sharpe (3Y)0.28 |
| Max drawdown (1Y)−78.3% |
| Max drawdown (3Y)−86.3% |
| Beta (3Y vs SPY)2.01 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 4.0M | $6M | 5.82% | −1.5% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.9M | $5M | 4.18% | new |
| Laurion Capital Management LP | 2.6M | $4M | 3.87% | +0.0% |
| Pfizer Inc | 2.4M | $4M | 3.53% | +0.0% |
| ACORN CAPITAL ADVISORS, LLC | 1.8M | $3M | 2.58% | −10.2% |
| GEODE CAPITAL MANAGEMENT, LLC | 1.6M | $3M | 2.34% | +5.0% |
| FRANKLIN RESOURCES INC | 1.2M | $2M | 1.76% | +0.0% |
| STATE STREET CORP | 1.2M | $2M | 1.74% | −0.4% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-14 | −$0.18 | — | $41,000 | −62.4% |
| 2025-12-31 | 2026-02-24 | — | — | $243,000 | +62.0% |
| 2025-09-30 | 2025-11-06 | −$0.17 | — | $120,000 | −27.3% |
| 2025-06-30 | 2025-07-29 | −$0.21 | — | $121,000 | −25.8% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-13 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
